KOREA WHO
-
-
-
CEO of Alteogen
Park Soon-jae
After Laying the Foundation for LG Group's Biopharmaceutical Business, Founder Aims for Global Pharma Leap with Proprietary Technology
-
Last Updated on Oct 11, 2024
-
CEO of Alteogen
Life Summary
Park Soon-jae is the CEO of Alteogen.
He aims to elevate Alteogen beyond the level of a biosimilar (biopharmaceutical generic drug) company, transforming it into a global pharmaceutical company that develops biobetters (improved biopharmaceuticals).
Park was born on December 22, 1954, in Gunsan, Jeollabuk-do.
He graduated from Seoul High School and earned a degree in biochemistry from Yonsei University. He later obtained a Ph.D. in chemistry from Purdue University in the United States.
Park worked as a researcher at the Massachusetts Institute of Technology (MIT) graduate school.
He joined Lucky Biotech Research Institute (now LG Chem Research Institute) as a senior researcher, where he led research, development, and regulatory approval of biopharmaceuticals.
Park played a pivotal role in advancing LG Chem’s biopharmaceutical business by launching eight biopharmaceutical products, including growth hormones, hepatitis B vaccines, and interferons.
He also led the global technology transfer of the quinolone antibiotic "Factive," the first domestically developed new drug to receive U.S. FDA approval.
Park later moved to Hanwha Petrochemical as Managing Director and Head of Bio Development, where he spearheaded the Dream Pharma business.
During his tenure as Vice Chairman and CEO at Binex, he secured private management rights for the government’s Korea Biotech Commercialization Center (KBCC).
In 2008, he co-founded Alteogen with his wife, Professor Jung Hye-shin, and became the company’s CEO in 2011.
His personal motto is "Live a life like a grain of wheat," reflecting his humble and service-oriented approach to leadership.
Park emphasizes a management principle that the company must have either a world-first or differentiated platform.
#ParkSoonjae #Alteogen #biopharmaceuticals #biosimilars #biobetters #globalpharma #biotech #Factive #LGchem #Binex #innovativeplatforms #leadership
He aims to elevate Alteogen beyond the level of a biosimilar (biopharmaceutical generic drug) company, transforming it into a global pharmaceutical company that develops biobetters (improved biopharmaceuticals).
Park was born on December 22, 1954, in Gunsan, Jeollabuk-do.
He graduated from Seoul High School and earned a degree in biochemistry from Yonsei University. He later obtained a Ph.D. in chemistry from Purdue University in the United States.
Park worked as a researcher at the Massachusetts Institute of Technology (MIT) graduate school.
He joined Lucky Biotech Research Institute (now LG Chem Research Institute) as a senior researcher, where he led research, development, and regulatory approval of biopharmaceuticals.
Park played a pivotal role in advancing LG Chem’s biopharmaceutical business by launching eight biopharmaceutical products, including growth hormones, hepatitis B vaccines, and interferons.
He also led the global technology transfer of the quinolone antibiotic "Factive," the first domestically developed new drug to receive U.S. FDA approval.
Park later moved to Hanwha Petrochemical as Managing Director and Head of Bio Development, where he spearheaded the Dream Pharma business.
During his tenure as Vice Chairman and CEO at Binex, he secured private management rights for the government’s Korea Biotech Commercialization Center (KBCC).
In 2008, he co-founded Alteogen with his wife, Professor Jung Hye-shin, and became the company’s CEO in 2011.
His personal motto is "Live a life like a grain of wheat," reflecting his humble and service-oriented approach to leadership.
Park emphasizes a management principle that the company must have either a world-first or differentiated platform.
#ParkSoonjae #Alteogen #biopharmaceuticals #biosimilars #biobetters #globalpharma #biotech #Factive #LGchem #Binex #innovativeplatforms #leadership